Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

US stocks in focus after Iran attacked US bases in Qatar. Investors often turn to dividend stocks for stability amidst ...

Initial public offerings (IPOs) just keep on coming in 2025 and they continue to remain in heavy demand. Companies have ...

AbbVie Inc. (NYSE: ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King ...

The trial judged the tolerability, safety and efficacy of atogepant, at 60 milligrams once daily, compared to the ...

Johnson & Johnson (NYSE:JNJ) said that an advisory committee of the EU drug regulator, the European Medicines Agency (EMA), ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

Patients with axSpA who received UPA reported rapid and sustained improvements in total and nocturnal back pain over 12 weeks.

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.